{
    "clinical_study": {
        "@rank": "133024", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of tretinoin in treating patients who\n      have any stage mycosis fungoides or Sezary syndrome."
        }, 
        "brief_title": "Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome", 
        "completion_date": {
            "#text": "August 2002", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Mycoses", 
                "Mycosis Fungoides", 
                "Sezary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the efficacy of tretinoin (TRA) in patients with mycosis\n      fungoides/Sezary syndrome. II. Evaluate the spectrum of toxicity of TRA in this patient\n      population.\n\n      OUTLINE: Nonrandomized study. Single-agent Chemotherapy. Tretinoin, All-trans-Retinoic Acid,\n      TRA, NSC-122758.\n\n      PROJECTED ACCRUAL: If 1 or more of the first 15 evaluable patients experience an objective\n      response, then 20 additional patients will be entered. It is anticipated that the accrual\n      rate will be 1-2 patients per month."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Biopsy-proven mycosis fungoides/Sezary syndrome Stage I-IV\n        disease No CNS involvement At least 1 measurable lesion required (skin, lymph nodes,\n        visceral lesion, or peripheral blood counts)\n\n        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-3 Hematopoietic: WBC at\n        least 3,000/mm3 Platelet count at least 75,000/mm3 Hepatic: Bilirubin no more than 2.0\n        mg/dL Transaminases no more than 2 x normal Alkaline phosphatase no more than 2 x normal\n        Renal: Creatinine no more than 2.0 mg/dL Other: No active systemic infection No\n        significant organ failure uncontrolled with medication No pregnant or lactating women\n        Effective contraception required of fertile women\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior systemic therapy\n        Chemotherapy: At least 4 weeks since prior topical chemotherapeutics or systemic therapy\n        Endocrine therapy: At least 4 weeks since prior topical (including steroid) therapy or\n        systemic therapy Radiotherapy: Not specified Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002479", 
            "org_study_id": "NCI T91-0136", 
            "secondary_id": [
                "NU-T91-0136", 
                "NCI-T91-0136O"
            ]
        }, 
        "intervention": {
            "intervention_name": "tretinoin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tretinoin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I cutaneous T-cell non-Hodgkin lymphoma", 
            "stage II cutaneous T-cell non-Hodgkin lymphoma", 
            "stage III cutaneous T-cell non-Hodgkin lymphoma", 
            "stage IV cutaneous T-cell non-Hodgkin lymphoma"
        ], 
        "lastchanged_date": "May 17, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome", 
        "overall_official": {
            "affiliation": "Robert H. Lurie Cancer Center", 
            "last_name": "Timothy M. Kuzel, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "citation": "Siegel RS, Martone B, Guitart J, et al.: Phase II trial of all-TRA in the treatment of relapsed/refractory mycosis fungoides. 94(1 suppl): A423, 96a, 1999."
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 1991", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Robert H. Lurie Comprehensive Cancer Center, Northwestern University": "41.878 -87.63"
    }
}